目的 探討復(fù)方苦參注射液聯(lián)合多西他賽和奈達(dá)鉑治療中晚期宮頸癌的臨床療效。方法 選取2012年6月-2015年6月遼寧省腫瘤醫(yī)院婦科收治的中晚期宮頸癌患者92例,根據(jù)治療方案的差別分為對(duì)照組和治療組,每組各46例。對(duì)照組靜脈滴注多西他賽注射液,70 mg/m²,每周1次;同時(shí)在每個(gè)化療周期的第一天靜脈滴注注射用奈達(dá)鉑,70 mg/m²。治療組在對(duì)照組治療基礎(chǔ)上靜脈滴注復(fù)方苦參注射液,20 mL加入250 mL生理鹽水,1次/d,連用14 d。兩組21 d為1個(gè)化療療程,兩組均連續(xù)治療2個(gè)療程。觀察兩組的臨床療效和生活質(zhì)量改善情況,同時(shí)比較兩組患者治療前后CD³⁺、CD⁴⁺、CD⁴⁺/CD⁸⁺、NK細(xì)胞的變化情況。結(jié)果 治療后,治療組和對(duì)照組治療有效率分別為65.22%、43.48%;臨床獲益率分別為89.13%、78.26%,兩組有效率、臨床獲益率比較差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。對(duì)照組和治療組生活質(zhì)量改善率分別為65.22%、84.78%,兩組比較差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。治療后,治療組CD³⁺、CD⁴⁺、CD⁴⁺/CD⁸⁺、NK細(xì)胞較治療前均有顯著增高,同組治療前后差異有統(tǒng)計(jì)學(xué)意義(P<0.05);治療后,治療組這些觀察指標(biāo)顯著高于對(duì)照組,兩組比較差異具有統(tǒng)計(jì)學(xué)意義(P<0.05)。對(duì)照組治療前后這些觀察指標(biāo)沒(méi)有顯著變化。治療組白細(xì)胞下降、血小板下降、骨髓抑制、胃腸道反應(yīng)、肝腎功能異常的發(fā)生例數(shù)均顯著低于對(duì)照組,兩組比較差異具有統(tǒng)計(jì)學(xué)意義(P<0.05)。結(jié)論 復(fù)方苦參注射液聯(lián)合多西他賽和奈達(dá)鉑治療中晚期宮頸癌具有較好的臨床療效,可改善患者的生活質(zhì)量,增加患者的細(xì)胞免疫功能,且不良反應(yīng)較少,具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical efficacy of Compound Kushen Injection combined with docetaxel and nedaplatin in treatment of medium-term and advanced cervical cancer. Methods Patients (92 cases) with medium-term and advanced cervical cancer in Department of Gynaecology of Liaoning Cancer Hospital from June 2012 to June 2015 were enrolled in this study. According to the different treatment plan, patients were divided into treatment (46 cases) and control (46 cases) groups. The patients in the control group were iv administered with Docetaxel Injection, 70 mg/m², once weekly. And they were iv administered with Nedaplatin for injection on the first day of each chemotherapy course, 70 mg/m². The patients in the treatment group were iv administered with Compound Kushen Injection, 20 mL added into 0.9% normal saline 250 mL, once daily, 14 d in one course. One course of treatment included 4 weeks, and two groups were treated for two courses. The clinical efficacy and improvement of life quality in two groups were evaluated, and the changes of CD³⁺, CD⁴⁺, CD⁴⁺/CD⁸⁺, and NK in two groups were compared. Results After treatment, the total effective rate of control group was 43.48%, and the clinical benefit rate was 78.26%, while the total effective rate of treatment group was 65.22%, and the clinical benefit rate was 89.13%, and there were differences between two groups (P < 0.05). The improvement rate of life quality in the control and treatment groups were 65.22% and 84.78%, respectively, and there were differences between two groups (P < 0.05). After treatment, CD³⁺, CD⁴⁺, CD⁴⁺/CD⁸⁺, and NK cells in treatment group were increased, and the difference was statistically significant in the same group (P < 0.05). After treatment, the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). The observation indexes in the control group did not change significantly before and after treatment. The cases of white blood cells decline, platelet decline, bone marrow suppression, gastrointestinal reaction, liver and kidney dysfunction in the treatment group were significantly lower than those in the control group, and there were differences between two groups (P < 0.05). Conclusion Compound Kushen Injection combined with docetaxel and nedaplatin has the good clinical effect in treatment of medium-term and advanced cervical cancer, and can improve the quality of life, also can increase cell immune function with less adverse reaction, which has a certain clinical application value.